Robert E. Hoffman
CIK 1166288 · Chief Executive Officer · last filed 2026-10-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ARNA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
6166 NANCY RIDER DRIVE
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Esperion Therapeutics, Inc. (ESPR) Delisted | Director | 0 | $3.18 | $0 | $0 | 4 | 2026-07-13 |
| FBLG | Director | — | $0.94 | — | $0 | 3 | 2026-06-23 |
| HURA | Director | — | $1.99 | — | $0 | 2 | 2026-02-17 |
| TuHURA Biosciences, Inc./NV (KTRA) Delisted | President, CEO and Interim CFO | 1,969 | $7.54 | $14.8K | $25.8K | 7 | 2023-09-01 |
| KURA | Director | — | $9.71 | — | $0 | 6 | 2021-06-23 |
| TuHURA Biosciences, Inc./NV (DMPI) Delisted | Director | — | — | — | $0 | 5 | 2020-06-30 |
| HRTX | CFO & SVP, Finance | 1,280 | $0.30 | $384 | -$1.15M | 5 | 2019-12-23 |
| Aravive, Inc. (ARAV) Delisted | Director | — | $0.04 | — | $0 | 3 | 2019-09-13 |
| CombiMatrix Corp (CBMX) Delisted | Director | 0 | — | — | $16.0K | 7 | 2017-11-16 |
| MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) Delisted | Director | 1,479 | — | — | $0 | 4 | 2017-05-23 |
| ARENA PHARMACEUTICALS INC (ARNA) Delisted | SVP, Finance and CFO | 5,807 | $99.99 | $580.6K | -$1.17M | 16 | 2014-12-17 |
Recent Filings · Page 4 of 8
72 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-11-13 | TuHURA Biosciences, Inc./NV (DMPI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-07-03 | HRTX | Mixed | +744 | -$676.4K | EDGAR |
| 2018-06-08 | KURA | Grant (A) | — | $0 | EDGAR |
| 2018-04-17 | TuHURA Biosciences, Inc./NV (DMPI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-12-20 | HRTX | Mixed | +536 | $7.0K | EDGAR |
| 2017-11-16 | CombiMatrix Corp (CBMX) Delisted | Mixed | −8,619 | $0 | EDGAR |
| 2017-06-12 | KURA | Grant (A) | — | $0 | EDGAR |
| 2017-05-23 | MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-04-24 | HRTX | Grant (A) | — | $0 | EDGAR |
| 2017-04-04 | MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) Delisted | Exer (M) | +1,543 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.